CP-107 Analisis of pharmacy interventions between 2010 and 2015

Background Pharmaceutical interventions are a key strategy to ensure proper drug prescription and the effectiveness and safety of any treatment. Purpose To study the pharmaceutical interventions made in hospitalised patients between 2010 and 2015. Material and methods Analysis of the interventions was derived from a retrospective observational study between 2010 and 2015 in hospitalised patients. Type of pharmaceutical intervention, resolution of the intervention and data on treatment were collected and analysed using a sheet developed for this purpose, and using an Access database. Results 23 232 pharmaceutical interventions were reported. The most common were: change of other drug included in hospital pharmacotherapeutic guide 50.85%, change of proposed dose 30.67%, administration error 3.5%, possible adverse events 2.95%, interactions 2.4%, monitoring recommendation 1.5% change and other 8.13%. Resolution of the recommendations were: accepted 43.19%, home medication (provided by the patient) 26.81%, no evaluation due to insufficient information 24.76% and rejected 5.24%. The therapeutic groups involved were mainly the following: group C (cardiovascular) 29.78%, group N (neurological) 25.06%, group B (blood and haematopoietic organs, particularly heparins) 9.43%, group J (anti-infectives) 9.18% and group A (gastrointestinal and metabolic) 6.45%. Conclusion The most common interventions were change of other drug included in the hospital pharmacotherapeutic guide and change of proposed dose. The percentage of interventions rejected was very low. The most common therapeutic groups were cardiovascular and neurologic. References and/or Acknowledgements Overhage JM, Lukes A. Practical, reliable, comprehensive method for characterizing pharmacists clinical activities. Am J Health Syst Pharm 1999;56:2444-50 Bates DW, Cullen DJ, Laird N, et al . Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995;274:29-34 No conflict of interest.